CompletedPhase 2NCT02692248
Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT
Studying Diffuse large B-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
- Principal Investigator
- Dolores Caballero, MDUniversity of Salamanca
- Intervention
- Ibrutinib(drug)
- Enrollment
- 64 enrolled
- Eligibility
- 18-99 years · All sexes
- Timeline
- 2016 – 2021
Study locations (17)
- Hospital Universitario Son Espases, Palma, Balearic Islands, Spain
- Hospital Especialidades, Jerez de la Frontera, Cádiz, Spain
- Hospital Universitario Donostia, Donostia / San Sebastian, Guipúzcoa, Spain
- Hospital de Navarra, Pamplona, Navarre, Spain
- Complexo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain
- Hospital Universitario Central de Asturias, Oviedo, Principality of Asturias, Spain
- Hospital Universitario Vall d'Hebron, Barcelona, Spain
- Hospital Clínic de Barcelona, Barcelona, Spain
- Complejo Hospitalario de Jaén, Jaén, Spain
- Hospital Universitario Infanta Leonor, Madrid, Spain
- MD Anderson Cancer Center, Madrid, Spain
- Hospital Universitario 12 de Octubre, Madrid, Spain
- Hospital General Universitario Morales Meseguer, Murcia, Spain
- Hospital Universitario Virgen del Rocío, Seville, Spain
- Hospital Clínic Universitari de València, Valencia, Spain
- +2 more locations on ClinicalTrials.gov
Collaborators
Janssen-Cilag, S.A.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02692248 on ClinicalTrials.govOther trials for Diffuse large B-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07365306Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaCity of Hope Medical Center
- RECRUITINGPHASE3NCT07493109Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOPOu Bai, MD/PHD
- RECRUITINGPHASE2NCT07493148Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCLOu Bai, MD/PHD
- RECRUITINGPHASE3NCT07409428A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCLHutchmed
- RECRUITINGPHASE2NCT07397832CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCLTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE3NCT07188558A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyLyell Immunopharma, Inc.
- RECRUITINGPHASE2NCT07499271Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 MutationThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE2NCT07189065A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell LymphomaGuangzhou Lupeng Pharmaceutical Company LTD.